...
首页> 外文期刊>Radiation oncology >Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch? patient registry
【24h】

Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch? patient registry

机译:从RSSearch ?患者注册中心开始的立体定向身体放疗,用于中心定位的早期非小细胞肺癌或肺转移

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background The purpose of this study was to evaluate treatment patterns and outcomes of stereotactic body radiotherapy (SBRT) for centrally located primary non-small cell lung cancer (NSCLC) or lung metastases from the RSSearch? Patient Registry, an international, multi-center patient registry dedicated to radiosurgery and SBRT. Methods Eligible patients included those with centrally located lung tumors clinically staged T1-T2 N0, M0, biopsy-confirmed NSCLC or lung metastases treated with SBRT between November 2004 and January 2014. Descriptive analysis was used to report patient demographics and treatment patterns. Overall survival (OS) and local control (LC) were determined using Kaplan-Meier method. Toxicity was reported using the Common Terminology Criteria for Adverse Events version 3.0. Results In total, 111 patients with 114 centrally located lung tumors (48 T1-T2,N0,M0 NSCLC and 66 lung metastases) were treated with SBRT at 19 academic and community-based radiotherapy centers in the US and Germany. Median follow-up was 17 months (range, 1–72). Median age was 74 years for primary NSCLC patients and 65 years for lung metastases patients (p?
机译:背景技术这项研究的目的是评估立体定位身体放疗(SBRT)对中心定位的原发性非小细胞肺癌(NSCLC)或RSSearch引起的肺转移的治疗模式和结果。 Patient Registry,一个专门用于放射外科和SBRT的国际,多中心患者注册表。方法符合条件的患者包括2004年11月至2014年1月间临床分期为T1-T2 N0,M0,活检证实的NSCLC或经SBRT治疗的肺转移灶的中心性肺肿瘤患者。采用描述性分析报告患者的人口统计学和治疗方式。使用Kaplan-Meier方法确定总生存期(OS)和局部控制(LC)。使用《不良事件通用术语标准》 3.0版报告了毒性。结果在美国和德国的19个学术和社区放疗中心中,总共对111例114例位于中心的肺部肿瘤(48例T1-T2,N0,M0 NSCLC和66例肺转移)进行了SBRT治疗。中位随访时间为17个月(范围1-72)。原发性NSCLC患者的中位年龄为74岁,肺转移患者的中位年龄为65岁(p <0.001)。 SBRT剂量以16到60 Gy(中位48 Gy)的剂量变化(以1-5个分数(中位数4个分数))输送。位于中心的原发性非小细胞肺癌的中位剂量为48 Gy,而肺转移的中位剂量为37.5 Gy(p?= 0.0001),原发性NSCLC的中位BED10为105.6 Gy,肺转移的中位BED10为93.6 Gy(p?= 0.0005)。 T1N0M0和T2N0M0 NSCLC的两年OS分别为79和32.1%(p≥0.009),而肺转移的两年OS为49.6%。原发性NSCLC和肺转移的两年LC分别为76.4%和69.8%。毒性低,没有3级或更高的急性或晚期毒性。结论总的来说,位于原发性NSCLC中心的患者比患有肺转移的患者年龄更大并且接受更高剂量的SBRT。尽管存在这些差异,但LC和OS对于SBRT治疗的中心性肺肿瘤患者还是有利的。报告的毒性很低,尽管在剂量耐受性接近或超过公布的指南的患者中观察到了低度毒性。需要进行前瞻性研究以进一步确定该组患者的最佳SBRT剂量。试用注册Clinicaltrials.gov标识符:NCT01885299网站

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号